Barry L. Carter

An internationally recognized expert in hypertension and team-based care, Barry Carter, ’78 BSPh, PharmD, has served on faculties at multiple universities, including the UI College of Pharmacy; University of Houston and Baylor College of Medicine; and the University of Colorado, where he was Department of Pharmacy Practice chair. Carter returned to the UI in 2000 and has since received more than $33 million in National Institutes of Health (NIH) funding as the principal investigator and another $43 million as a co-investigator. 

 Carter is past president of the American College of Clinical Pharmacy (ACCP). He has been named a fellow of the American Heart Association Council on High Blood Pressure Research, ACCP, and the American Society of Hypertension. Carter was a member of the National Heart, Lung, and Blood Institute’s Fifth, Sixth, Seventh, and Eighth Joint National Committees on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. He continues to collaborate with UI investigators on NIH grants involving hypertension management or cardiovascular disease.

Valerie E. Jensen

Valerie Jensen, ’90 BSPh, is associate director of the Drug Shortage Staff at the U.S. Food and Drug Administration (FDA). She leads a dedicated team that has prevented hundreds of drug shortages throughout the years by working with the pharmaceutical industry and multiple stakeholders. 

Upon her UI graduation, Jensen joined the U.S. Public Health Service (USPHS) as a commissioned officer. Her 
first duty station was the Whiteriver Indian Hospital in Whiteriver, Arizona, where she completed a postgraduate year one (PGY1) residency in Ambulatory Care. Jensen transferred to the FDA in 1999 and was one of the initial developers of its Drug Shortage Program. She was promoted to the rank of captain in 2009. 

Jensen was deployed by the USPHS as a pharmacist to multiple national disaster events, including Hurricane Katrina where she was responsible for pharmacy services in temporary medical facilities. She retired from active duty after 30 years of service in July 2020 and was hired back into her same FDA position as a civilian one week later at the height of the pandemic. Jensen has thoroughly enjoyed precepting UI pharmacy students at the FDA.

David W. Miller

David Miller, ’83 BSPh, PhD, built a career operating at the intersection of science, medicine, and economics. He currently is chair and chief executive officer of Genesis Research Group, a pharma services consultancy, and is an operating partner at GHO Capital. Miller began his career at Glaxo (now GSK) in pharmacoeconomics where he was hired by Jane Osterhaus, ’81 BSPh, PhD. He also has held executive roles at Elan and Biogen.

A sought-after advisor, mentor, and board member, Miller serves on boards at Eliquent; Aitia; Almaden Genomics; the University of Maryland, Baltimore (UMB) School of Pharmacy; and the UI College of Pharmacy (Executive Leadership Board). He previously sat on boards with the National Pharmaceutical Council, the University of California San Francisco School of Pharmacy, and the American Foundation for Pharmaceutical Education. Miller earned his PhD at UMB, studying health economics and policy. 

Miller and his wife, Wendy, and their two sons, Trey and Grady, have made London, UK, their home for more than 20 years.